Editorial response: Meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides

Clinical Infectious Diseases

Volumn 24, Issue 5, 1997, Pages 816-819

  Gilbert, David N ^a  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; GENTAMICIN; ISEPAMICIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; EDITORIAL; GRAM NEGATIVE INFECTION; HUMAN; META ANALYSIS; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BACTERIAL INFECTION; DRUG ADMINISTRATION; MICROBIOLOGY; NOTE; TREATMENT OUTCOME;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; META-ANALYSIS; TREATMENT OUTCOME;

EID: 0031133579     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/24.5.816     Document Type: Editorial

References (15)

1. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991;35:399-405.
2. Daikos GL, Jackson GG, Lolans VT, Livermore DM. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis 1990;162:414-20.
3. Daikos GL, Lolans VT, Jackson GG. First exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning of optimal clinical use. Antimicrob Agents Chemother 1991;35:117-23.
4. Barclay ML, Begg EJ, Chambers ST. Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. Antimicrob Agents Chemother 1992;36:1951-7.
5. Barclay ML, Begg EJ, Chambers ST, Thornley PE, Pattemore PK, Grimwood K. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. J Antimicrob Chemother 1996;37:1155-64.
6. Gilbert DN. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:279-306.
7. Barza M, Ioannidis JPA, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996;312:338-45.
8. Munckhof WJ, Grayson JL, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996;37:645-63.
9. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996;124:717-25.
10. Galloe AM, Gaudal N, Christensen HR, Kampmann JP. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995;48:39-43.
11. Ferriols-Lisart R, Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. American Journal of Health Systems Pharmacy 1996;53:1141-50.
12. Klastersky J, Prévost JM, Meunier-Carpentier F, Daneau D, Gerard M. Comparative trials of single dose versus twice daily sisomicin in bacteriuric patients. J Clin Pharmnacol 1997;17:520-8.
13. Nordstrom L, Ringberg H, Cronberg S, Tjernstrom O, Walder M. Does administration of an aminoglycoside in single daily dose affect its efficacy and toxicity? J Antimicrob Chemother 1990;25:159-73.
14. Hansen M, Achen F, Carstensen C, et al. Once- versus thrice-daily dosing of netilmicin in febrile immunocompromised patients: a randomized, controlled study of efficacy and safety. Journal of Drug Development 1988;1(suppl 3):119-24.
15. Muijsken MA, Vreede RW, Van Dijk WC, Haverkom MJ, Kaufman L, Derde MP. A randomized clinical study of efficacy and safety of once daily versus conventional dosing of netilmicin in patients with severe infections. Journal of Drug Development 1988;1(suppl 3):145-6.